Catalent to Boost U.S. Production of Moderna’s Covid-19 Vaccine
Moderna has expanded its existing agreement with Catalent to boost COVID-19 vaccine production at Catalent’s fill-and-finish facility in Bloomington, Ind., to supply the U.S. market.
Under an existing pact signed in June 2020, Catalent helped fill an initial U.S. government order of 100 million doses of vaccine by the end of March, with a further order of 100 million doses scheduled for delivery by the end of May and a final shipment of 100 million additional doses planned by the end of July.
Under the expanded deal, Catalent is dedicating a new high-speed filling line at its Bloomington site to vaccine production starting next month and will reportedly be able to supply an additional 80 million vaccine doses annually.
The Bloomington plant has also been providing manufacturing and packaging services for the Johnson & Johnson (J&J) COVID-19 vaccine for U.S. distribution. And Catalent is also producing the J&J vaccine at its facility in Anagni, Italy, for distribution in Europe. ― Jason Scott